---
title: "HLI: Industry leader in M&A and restructuring with strong growth, diversification, and shareholder focus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294256940.md"
description: "A global leader in M&A, restructuring, and valuation advisory, the firm delivers strong, consistent financial performance with a diversified, data-driven business model. Growth is driven by organic hiring, strategic acquisitions, and a scalable, capital-light structure, supporting robust shareholder returns and industry leadership.Original document: Houlihan Lokey, Inc. [HLI] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-29T20:28:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294256940.md)
  - [en](https://longbridge.com/en/news/294256940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294256940.md)
generator: "portal-rs"
---

# HLI: Industry leader in M&A and restructuring with strong growth, diversification, and shareholder focus

A global leader in M&A, restructuring, and valuation advisory, the firm delivers strong, consistent financial performance with a diversified, data-driven business model. Growth is driven by organic hiring, strategic acquisitions, and a scalable, capital-light structure, supporting robust shareholder returns and industry leadership.

Original document: Houlihan Lokey, Inc. \[HLI\] Slides Release — Jul. 29 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [HLI.US](https://longbridge.com/en/quote/HLI.US.md)

## Related News & Research

- [Houlihan Lokey, Inc. $HLI Shares Sold by NewEdge Advisors LLC](https://longbridge.com/en/news/296200313.md)
- [Is Weaker Q2 Performance And New Shelf Registration Altering The Investment Case For Houlihan Lokey (HLI)?](https://longbridge.com/en/news/295878774.md)
- [GN: Gross margin rose to 52.1% as new launches offset a 4% organic revenue decline](https://longbridge.com/en/news/296382996.md)
- [Weekly Recap: 2026 organic revenue outlook raised and DKK1.0bn share buyback](https://longbridge.com/en/news/296738910.md)
- [PEB: Draft Medicare coverage for Cxbladder tests marks a pivotal step toward renewed growth](https://longbridge.com/en/news/296426151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**